OS THERAPIES INCORPORATED Debt Instrument, Convertible, Carrying Amount of Equity Component
OS THERAPIES INCORPORATED (OSTX) had Debt Instrument, Convertible, Carrying Amount of Equity Component of $1.35 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent · last filed 2026-08-14
- 2026-06-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $1.35M.
| Period end | Debt Instrument, Convertible, Carrying Amount of Equity Component |
|---|---|
| 2026-06-30 | $1.35M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |